Author's response to reviews

Title: Prostate tumor overexpressed 1 overexpression correlates with tumor progression and predicts poor prognosis in breast cancer

Authors:

Fangyong Lei (leify@sysucc.org.cn)
Longjuan Zhang (zhlongj@mail.sysu.edu.cn)
Xinghua Li (xinghuali22@gmail.com)
Xi Lin (linxi@sysucc.org.cn)
Shu Wu (wushu@sysucc.org.cn)
Fengyan Li (lify@sysyucc.org.cn)
Junling Liu (liujl@sysucc.org.cn)

Version: 2 Date: 13 May 2014

Author's response to reviews:

May, 13th, 2014

Dear editor,

Thank you for your decision letter of April 14th, 2014 regarding our manuscript MS: 1179119073123351, entitled “Prostate tumor overexpressed 1 overexpression correlates with tumor progression and predicts poor prognosis in breast cancer” by Fangyong Lei et al., and for the opportunity of resubmitting a revised manuscript to BMC Cancer. We have very carefully studied all the points raised by editor and reviewers and have added necessary data to address the reviewers’ concerns. We have changed the title to “Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer” and are now submitting a revised manuscript with point-to-point response to the critiques to BMC Cancer.

We also would like to thank you for important suggestion, to which we have made modifications as follows:

1. We summarized ER status, PR status, HER2 status and P53 status of the tested cell lines in supplemental Table 1 and analyzed the correlation between PTOV1 expression and these statuses of the cell lines as the reviewers suggested.

2. We have made modifications to clarify the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was as reference gene that acts as an internal reference to normalize the mRNA expression.

3. We included the analysis correlation of PTOV1 with PR and HER-2 in Table 3.

4. In Figure 4, the survival curves were modified to start from 100% as the reviewer 2 suggested.

We hope that you will find our revised manuscript suitable for publication in BMC.
Cancer. Your supportive consideration is greatly appreciated.

Best wishes,

Junling Liu, MD  
State Key Laboratory of Oncology in South China,  
Department of Medical Oncology,  
Sun Yat-sen University Cancer Center,  
Guangzhou 510060, P.R.China.  
E-mail: liujl@sysucc.org.cn